<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474785</url>
  </required_header>
  <id_info>
    <org_study_id>#111237</org_study_id>
    <secondary_id>R01DK091748</secondary_id>
    <nct_id>NCT01474785</nct_id>
  </id_info>
  <brief_title>RYGB and the Gastric Adipose Axis</brief_title>
  <official_title>RYGB Improves Metabolism by Interrupting the Gastric Adipose Tissue Axis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if interruption in gastric-adipose tissue axis
      signaling contributes to early improvements in oxidative stress, insulin sensitivity, and
      inflammation, and to determine if interruption of the stomach in RYGB results in reduction of
      plasma acylated ghrelin (AG) and in an altered acylated ghrelin:unacylated ghrelin (AG:UAG)
      ratio which may contribute to decreased oxidative stress and improved insulin sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in glucose disposal rate</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Glucose disposal rate is a sensitive laboratory procedure for determining how your body uses sugar (called insulin sensitivity).</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>RYGB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Roux-en-Y gastric bypass surgery (RYGB) subjects to undergo hyperinsulinemic-euglycemic clamp with human ghrelin infusion pre-operatively and post-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VSG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vertical sleeve gastrectomy (VSG) subjects to undergo hyperinsulinemic-euglycemic clamp pre-operatively and post-operatively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Calorie Diet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive very low calorie diet prescribed for RYGB patients and undergo hyperinsulinemic-euglycemic before and after diet.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>human ghrelin</intervention_name>
    <description>0.5-1 pmol/kg.min of human ghrelin administered by IV two times</description>
    <arm_group_label>RYGB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>very low calorie diet</intervention_name>
    <description>standard very low calorie diet that is prescribed for all RYGB patients after their operation</description>
    <arm_group_label>Low Calorie Diet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hyperinsulinemic/Euglycemic Clamp</intervention_name>
    <description>Insulin and glucose infusions to measure glucose kinetics.</description>
    <arm_group_label>RYGB</arm_group_label>
    <arm_group_label>VSG</arm_group_label>
    <arm_group_label>Low Calorie Diet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL I

        Inclusion Criteria:

          -  Age 18-65 years

          -  BMI â‰¥ 35 kg/m^2

          -  Scheduled for bariatric surgery

          -  Considering bariatric surgery

          -  Waiting for insurance approval for bariatric surgery

          -  Currently not considering bariatric surgery, but otherwise eligible

          -  Enrollment in medical weight loss program

        Exclusion Criteria:

          -  Smoking &gt;7 cigarettes per day

          -  Precious malabsorptive or restrictive intestinal surgery

          -  Pregnant or breastfeeding

          -  Recent history of neoplasia (5&lt;years ago)

          -  Malabsorptive syndromes

          -  Inflammatory intestinal disease

          -  Established organ disfunction

          -  Allergy to acetaminophen
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naji Abumrad, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 15, 2011</study_first_submitted>
  <study_first_submitted_qc>November 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2011</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Naji Abumrad</investigator_full_name>
    <investigator_title>Professor of Surgery, Chairman Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Bariatric surgery</keyword>
  <keyword>Nashville, Tennessee</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

